Principal Investigator
Amer Beitinjaneh
Enrollment Status
Closed
Clinical Trial ID
Institutional Protocol #
20220279
Clinical Trial Summary
Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination with Programmed Cell Death Protein-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients after Failure of Frontline
Therapy (ACTION)
Phase
Phase I
Funding Agency/Sponsor
Industrial
Disease
Lymphoma
Contact Information
Phone Number
+1 (305) 2434624